MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00467-022-05636-9

Медицинская библиотека · Pediatric nephrology (Berlin, Germany) · 2022

X-linked hypophosphatemia, obesity and arterial hypertension: data from the XLH21 study.

Bloudeau Louisa, Linglart Agnès, Flammier Sacha, Portefaix Aurélie, Bertholet-Thomas Aurélia, Eddiry Sanaa, Barosi Anna, Salles Jean-Pierre, Porquet-Bordes Valérie, Rothenbuhler Anya, Roger Christelle, Bacchetta Justine

Многоцентровое исследованиеСтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

The underlying mechanisms of obesity in X-linked hypophosphatemia (XLH) are not known. We aimed to evaluate whether FGF21, an endocrine FGF involved in the regulation of carbohydrate-lipid metabolism, could be involved.

METHODS

We performed a prospective multicenter cross-sectional study comparing FGF23, Klotho, and FGF21 levels in teenagers with XLH compared to healthy controls (VITADOS cohort) after matching for age, gender, and puberty. Non-parametric tests were performed (results presented as median (min-max)).

RESULTS

A total of 40 XLH teenagers (n = 20 Standard Of Care, SOC, n = 20 burosumab) were included. While patients receiving burosumab displayed increased BMI as compared to patients receiving SOC, systolic blood pressure expressed as percentile was progressively and significantly lower when comparing the three groups: 77 (4-99) in SOC, 47 (9-98) in burosumab, and 28 (1-94) in controls (p = 0.007). When compared to patients receiving SOC, patients receiving burosumab displayed significantly increased phosphate and 1,25(OH)2D levels. We found increased Klotho levels in patients receiving burosumab. No differences were found for either carbohydrate-lipid biomarkers or FGF21 between the three groups. A total of 21 XLH patients (53%) had insulin resistance (HOMA > 2.4, N = 10 SOC, N = 11 burosumab).

CONCLUSION

FGF21 does not explain obesity/overweight in XLH. Of note, this study was performed in France in 2018-2019, early after the approval authorizing burosumab only in case of severe XLH despite SOC. As such, the data on systolic blood pressure highlighting a possible impact of burosumab to decrease blood pressure as well as increase Klotho levels deserve further studies given their potential effect on long-term cardiovascular risk. A higher resolution version of the Graphical abstract is available as Supplementary information.

Для цитирования: Bloudeau Louisa, Linglart Agnès, Flammier Sacha, Portefaix Aurélie, Bertholet-Thomas Aurélia, Eddiry Sanaa, Barosi Anna, Salles Jean-Pierre, Porquet-Bordes Valérie, Rothenbuhler Anya, Roger Christelle, Bacchetta Justine. X-linked hypophosphatemia, obesity and arterial hypertension: data from the XLH21 study.. Pediatric nephrology (Berlin, Germany). 2022. DOI: 10.1007/s00467-022-05636-9.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.